SecBot SecBot
8-K ·Filed Oct 2, 2026

POSC

POSITRON CORP
BEARISH
Impact 6/10
Horizonmonths Processed24d 15h ago SEC0001539497-26-002637
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

Monitor the company's next quarterly filing for cash burn rate and whether the $2M debt is used for operations or growth. The 20% interest rate and related-party nature suggest limited access to conventional financing.

DirectionBearish
Confidencehigh
Horizonmonths
Latest settled — T+5d
POSC ▼ -7.07% at T+5d
SHORT call ✓ call won +7.07% · α vs SPY +7.49% · entry $1.84 → $1.71
Next anchor: T+20d in 3d
Latest observation: T+14 +10.13% FF3 residual α
Entry = T+0 close
Oct 2, 2026
via day close
T+1d
-2.39%
call +2.39% · α +2.94%
$1.80
settled 22d ago
T+5d
-7.07%
call +7.07% · α +7.49%
$1.71
settled 18d ago
T+20d
Pending
in 3d
T+60d
Pending
in 2mo

Price Chart

Loading chart...

Executive Summary

Positron Corporation issued $2,000,000 in unsecured promissory notes at 20% interest to affiliated investors (George Ortiz and TISU Investments) and one third party, due September 2027. As additional consideration, the company issued warrants to purchase 400,000 shares at $2.00/share, exercisable through 2030. Separately, George Ortiz exercised existing warrants for 300,000 shares at $1.50/share, providing $450,000 in gross proceeds. The high-interest debt from related parties and warrant dilution signal financial strain.

Key Financial Metrics

Deal Value
$2.0M
Deal Type
credit_facility

Key Facts

  • Issued $2,000,000 aggregate principal in unsecured promissory notes at 20% annual interest, due September 30, 2027.
  • $1,500,000 note issued to affiliated investor George Ortiz; $400,000 note to TISU Investments (controlled by director Tis Prager); $100,000 to an unrelated third party.
  • Issued warrants to purchase 400,000 shares of common stock at $2.00/share, exercisable through December 31, 2030.
  • George Ortiz exercised existing warrants for 300,000 shares at $1.50/share, generating $450,000 in gross proceeds.
  • Notes and warrants issued in unregistered transactions under Section 4(a)(2) and Rule 506 of Regulation D.

Financial Impact

$2,000,000 in new debt at 20% interest, plus potential dilution from 400,000 warrants exercisable at $2.00/share.

debtdilutioninterest expense

Risk Factors

  • High 20% interest rate on $2M debt increases financial burden.
  • Potential dilution from 400,000 warrants at $2.00/share if exercised.
  • Related-party lending may indicate difficulty raising capital from arms-length sources.
  • Maturity in September 2027 creates refinancing risk.

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001539497-26-002637
Document: n5417_x8-8k.htm0001539497-26-002637
Document: n5417x8_ex10-1.htm0001539497-26-002637
Document: 0001539497-26-002637-index-headers.html0001539497-26-002637
Document: 0001539497-26-002637-index.html0001539497-26-002637
Document: 0001539497-26-002637.txt0001539497-26-002637

US Market Status

Market Closed — Opens in 1h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 2, 2026